Human SPARC Antibody

Catalog # Availability Size / Price Qty
MAB941-SP
MAB941-100
MAB941-500
SPARC/Osteonectin in Human Ovary Cancer Tissue.
3 Images
Product Details
Citations (10)
FAQs
Supplemental Products
Reviews (2)

Human SPARC Antibody Summary

Species Reactivity
Human
Specificity
Detects human SPARC/Osteonectin in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse SPARC/Osteonectin is observed.
Source
Monoclonal Mouse IgG1 Clone # 122511
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human SPARC
Ala18-Ile303
Accession # P09486
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
ELISA

This antibody functions as an ELISA capture antibody when paired with Goat Anti-Human SPARC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF941).

This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Human SPARC DuoSet ELISA Kit (Catalog # DY941-05) for convenient development of a sandwich ELISA or the Human SPARC Quantikine ELISA Kit (Catalog # DSP00) for a complete optimized ELISA.

 
Immunohistochemistry
8-25 µg/mL
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Intracellular Staining by Flow Cytometry
0.25 µg/106 cells
See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry SPARC/Osteonectin antibody in Human Ovary Cancer Tissue by Immunohistochemistry (IHC-P). View Larger

SPARC/Osteonectin in Human Ovary Cancer Tissue. SPARC/Osteonectin was detected in immersion fixed paraffin-embedded sections of human ovarian clear cell carcinoma tissue using Human SPARC/Osteonectin Monoclonal Antibody (Catalog # MAB941) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Intracellular Staining by Flow Cytometry Detection of SPARC antibody in HT1080 Human Cell Line antibody by Flow Cytometry. View Larger

Detection of SPARC in HT1080 Human Cell Line by Flow Cytometry. HT1080 human fibrosarcoma cell line was stained with Mouse Anti-Human SPARC Monoclonal Antibody (Catalog # MAB941, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.

Human SPARC ELISA Standard Curve. Recombinant Human VSIG8 protein was serially diluted 2-fold and captured by Mouse Anti-Human VSIG8 Monoclonal Antibody (Catalog # MAB9418) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SPARC Antigen Affinity-purified Polyclonal Antibody (Catalog # AF941) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: SPARC

SPARC, an acronym for “secreted protein, acidic and rich in cysteine”, is also known as osteonectin or BM-40 (1-5). It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 286 amino acid (aa), 43 kDa protein contains an N-terminal acidic region that binds calcium, a follistatin domain that contains Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs (1-5). Crystal structure modeling shows that residues implicated in cell binding, inhibition of cell spreading, and disassembly of focal adhesions cluster on one face of SPARC, while a collagen binding epitope and an N-glycosylation site are opposite this face (6). SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling (3, 7). SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation (3-5). For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF (3-5). SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis (5, 8). SPARC is potentially cleaved by metalloproteinases, producing an angiogenic peptide that includes the copper-binding sequence KGHK (7). Paradoxically, SPARC is highly expressed in many tumor types undergoing an endothelial to mesenchymal transition; its expression, however, mainly decreases the likelihood of metastasis and confers sensitivity to chemotherapy and radiation (4, 9-11). Stabilin-1, which is expressed on alternately activated macrophages, is the first SPARC receptor to be identified. It binds the SPARC EC domain and mediates endocytosis for degradation (12). Mature human SPARC shows 92%, 92%, 97%, 99%, 96% and 85% aa identity with mouse, rat, canine, bovine, porcine and chick SPARC, respectively.

References
  1. Lankat-Buttgereit, B. et al. (1988) FEBS Lett. 236:352.
  2. Sweetwyne, M. T. et al. (2004) J. Histochem. Cytochem. 52:723.
  3. Sage, H. et al. (1989) J. Cell Biol. 109:341.
  4. Framson, P. E. and E. H. Sage (2004) J. Cell. Biochem. 92:679.
  5. Alford, A. I. and K. D. Hankenson (2006) Bone 38:749.
  6. Hohenester, E et al. (1997) EMBO J. 16:3778.
  7. Sage, E. H. et al. (2003) J. Biol. Chem. 278:37849.
  8. Delany, A. M. et al. (2003) Endocrinology 144:2588.
  9. Robert, G. et al. (2006) Cancer Res. 66:7516.
  10. Koblinski, J. E. et al. (2005) Cancer Res. 65:7370.
  11. Tai, I. T. et al. (2005) J. Clin. Invest. 115:1492.
  12. Kzhyshkowska, J. et al. (2006) J. Immunol. 176:5825.
Long Name
Secreted Protein Acidic and Rich in Cysteine
Entrez Gene IDs
6678 (Human); 20692 (Mouse)
Alternate Names
Basement-membrane protein 40; BM-40; ONcysteine-rich protein; Osteonectin; Secreted protein acidic and rich in cysteine; secreted protein, acidic, cysteine-rich (osteonectin); SPARC

Product Datasheets

You must select a language.

x

Citations for Human SPARC Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

10 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. PAI-1 uncouples integrin-?1 from restrain by membrane-bound ?-catenin to promote collagen fibril remodeling in obesity-related neoplasms
    Authors: Lin, LL;Nayak, B;Osmulski, PA;Wang, E;Wang, CP;Valente, PT;Wang, CM;Tan, X;Santanam, N;Wang, TL;Gaczynska, ME;Kost, ER;Huang, TH;Kirma, NB;
    Cell reports
    Species: Human
    Sample Types: Whole Cells
    Applications: Western Blot
  2. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer’s disease
    Authors: Jessica S. Sadick, Michael R. O’Dea, Philip Hasel, Taitea Dykstra, Arline Faustin, Shane A. Liddelow
    Neuron
  3. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis
    Authors: Xiaobo Zhou, Lan Zhang, Caihang Qierang, Min Huang, Xin Yang, Liangang Li et al.
    Translational Cancer Research
  4. Transcriptomic Bioinformatic Analyses of Atria Uncover Involvement of Pathways Related to Strain and Post-translational Modification of Collagen in Increased Atrial Fibrillation Vulnerability in Intensely Exercised Mice
    Authors: Yena Oh, Sibao Yang, Xueyan Liu, Sayantan Jana, Farzad Izaddoustdar, Xiaodong Gao et al.
    Frontiers in Physiology
  5. Osteoblast differentiation of equine induced pluripotent stem cells
    Authors: A Baird, T Lindsay, A Everett, V Iyemere, YZ Paterson, A McClellan, FMD Henson, DJ Guest
    Biol Open, 2018-05-10;0(0):.
    Species: Equine
    Sample Types: Whole Cells
    Applications: ICC
  6. Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers
    Authors: SH Mauzo, DR Milton, VG Prieto, CA Torres-Cab, WL Wang, N Chakravart, P Nagarajan, MT Tetzlaff, JL Curry, D Ivan, RE Brown, PP Aung
    Ann Diagn Pathol, 2018-03-15;34(0):151-154.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  7. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
    Authors: Puyuan Xing, Yixiang Zhu, Ling Shan, Sipeng Chen, Xuezhi Hao, Junling Li
    Oncotarget
  8. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
    Authors: E Borazanci, SZ Millis, J Kimbrough, N Doll, D Von Hoff, RK Ramanathan
    J Gastrointest Oncol, 2017-02-01;8(1):164-172.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  9. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.
    Authors: Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB
    Glia, 2006-06-01;53(8):845-57.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  10. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.
    Authors: Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A, Pandey A
    Mol. Cell Proteomics, 2005-10-08;5(1):157-71.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human SPARC Antibody

Average Rating: 5 (Based on 2 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human SPARC Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human SPARC Antibody
By Anonymous on 11/08/2019
Application: ELISA Sample Tested: Serum and Plasma Species: Human

Human SPARC Antibody
By Anonymous on 01/09/2018
Application: ELISA Sample Tested: Recombinant protein Species: Human